当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2012年第16期
编号:12231066
心力衰竭表观遗传药理学研究进展(4)
http://www.100md.com 2012年6月5日 《中国医药导报》 2012年第16期
     [12] Divakaran V,Mann DL. The emerging role of microRNAs in cardiac remodeling and heart failure [J]. Circ Res,2008,103(6):1072-1083.

    [13] Thum T,Cross C,Fiedler J,et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts [J]. Nature,2008,456(7224):980-984.

    [14] Zorio E,Medina P,Rueda J,et al. Insights into the role of microRNAs in cardic diseases:from biological signaling to therapeatic targets [J]. Cardiovasc Hematol Agents Med Chem,2009,7(1):82-90.

    [15] Puceat M. Pharmacological approaches to regenerative strategies for the treatment of cardiovascular diseases [J]. Curr Opin Pharmacol,2008,8(8):189-192.

    [16] Gomez A,Ingelman SM. Pharmacoepigenetics:its role in interindividual differences in drug response [J]. Clin Pharmacol Ther,2009,85(4):226-230.

    [17] Turan N,Katar S,Coutifaris C,et al. Explaining interindividual variability in phenotype:is epigenetics up to the challenges? [J]. Epigenetics,2010,5(1):16-19.

    [18] Mishra PK,Tyagi N,Kumar M,et al. MicroRNAs as a therapeutic target for cardiovascular diseases [J]. J Cell Mol Med,2009,13(4):778-789.

    (收稿日期:2012-01-13 本文编辑:张瑜杰), 百拇医药(岳语喃 杨水祥)
上一页1 2 3 4